Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Detaylı Bibliyografya
Asıl Yazarlar:	Mihaylova, B, Briggs, A, Hlatky, M, Armitage, J, Parish, S, Gray, A, Collins, R, Study, HP
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2009

Benzer Materyaller

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
Yazar:: Kent, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
Yazar:: Hopewell, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Statins for people at low risk of cardiovascular disease reply
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
Yazar:: Hopewell, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
Yazar:: Hopewell, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
Yazar:: Hopewell, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Economic evaluation of the Heart Protection Study
Yazar:: Briggs, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the United Kingdom and United States
Yazar:: Lui, JNM, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
Yazar:: Collins, R, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials
Yazar:: Cholesterol Treatment Trialists' Collaboration, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Misrepresentation of statin safety evidence.
Yazar:: Armitage, J, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
Yazar:: Hopewell, J, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States
Yazar:: Juliana Nga Man Lui, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
Yazar:: Armstrong SO, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Statin use for cardiovascular disease prevention: perceptions among people living with HIV in the United States
Yazar:: Adedotun Ogunbajo, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant datasets
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Hospital costs associated with adverse events in people with diabetes in the UK
Yazar:: Keng, MJ, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
Yazar:: Link, E, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States
Yazar:: Mitchell Aaron P, ve diğerleri
Baskı/Yayın Bilgisi: (2012-07-01)

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
Yazar:: Mihaylova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Lessons from the controversy over statins - Authors' reply.
Yazar:: Armitage, J, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Safety and efficacy of statins - Authors' reply
Yazar:: Collins, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

The safety of statins in clinical practice.
Yazar:: Armitage, J
Baskı/Yayın Bilgisi: (2007)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
Yazar:: Borislava Mihaylova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Statins and the progression of age-related macular degeneration in the United States.
Yazar:: Cassie A Ludwig, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Statins and the progression of age-related macular degeneration in the United States
Yazar:: Cassie A. Ludwig, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.
Yazar:: Margaritis, M, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Familial Resemblance in Low‐Density Lipoprotein Cholesterol Response to Statins in the Danish Population
Yazar:: Giulia Corn, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Yazar:: Mangravite, L, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
Yazar:: Mangravite, L, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Yazar:: Kearney, P, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyResearch in context
Yazar:: Borislava Mihaylova, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
Yazar:: Wu, R, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
Yazar:: Thalmann, I, ve diğerleri
Baskı/Yayın Bilgisi: (2022)